Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07826455) titled 'A Study to Evaluate Tegoprazan as a Diagnostic Tool for GERD' on Sept. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: HK inno.N Corporation
Condition:
GERD (Gastroesophageal Reflux Disease)
Intervention:
Drug: Tegoprazan 50 mg
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: September 1, 2026
Target Sample Size: 100
To know more, visit https://clinicaltrials.gov/study/NCT07826455
Publis...